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ABSTRACT 
Coronavirus SARS-CoV-2 (COVID-19) infection has become a global infection with high 
mortality and morbidity rate. The pathophysiology of COVID-19 has not yet clear but 
associated with increasing proinflammatory cytokines and chemokines that leads to cytokine 
storm. Cytokine storm leads to increasing coagulation that defined by increasing D-dimer, 
Prothrombin Time (PT), and activated partial thromboplastin time (aPTT). The use of 
anticoagulant in patient with COVID-19 decrease the mortality rate and become one of the 
recommended therapy.   
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ABSTRAK 
Virus korona SARS-CoV-2 (COVID-19) telah menjadi infeksi global dengan angka mortalitas 
dan morbiditas yang tinggi. Patofisiologi dari COVID-19 ini masih belum jelas dan dikaitkan 
dengan peningkatan sitokin dan kemokin inflamasi yang menyebabkan badai sitokin. Badai 
sitokin ini menyebabkan peningkatan koagulasi dan ditandai dengan peningkatan D-dimer, 
Prothrombin Time (PT), dan activated partial thromboplastin time (aPTT). Pemberian 
antikoagulan pada pasien COVID-19 terbukti dapat mengurangi angka mortalitas sehingga 
menjadi salah satu terapi yang dianjurkan. 
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INTRODUCTION 
Coronaviruses (CoVs) are 
enveloped RNA viruses with club-like 
spikes, exceptionally large RNA genome, 
and has different replication strategy 
compare to other viruses as its characters. 
Coronaviruses affects to mammals and 
poultry including humans and cause many 
types of sign and symptoms. Types of 
coronaviruses that have caused endemic to 
humans are Severe Acute Respiratory 
Syndrome coronavirus (SARS-CoV) and 
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Middle Eastern Respiratory Syndrome 
Coronavirus (MERS-CoV).1 
 Coronaviruses SARS-CoV-2 is the 
caused of COVID-19, which has become a 
global infection with high mortality and 
morbidity rates. In Indonesia, the first 
finding happened on March 2, 2020 and 
increase continuously while spreading 
throughout Indonesia with mortality rate 
around 6,7% of all positive cases.2 
 COVID-19 could be associated with 
higher mortality rate in patient with 
comorbidity as hypertension, diabetes, 
coronary heart disease, tumour, chronic 
obstructive pulmonary disease, chronic 
kidney disease, tuberculosis, asthma, and 
hepatitis B.3-5 
 
US CDC shown that some 
underlying disease are more at risk to 
Intensive Care Unit (ICU) admission as 
diabetes mellitus, cardiovascular disease, 
chronic lung disease, and chronic kidney 
disease.3 
 Patient with COVID-19 frequently 
show symptoms as fever, cough, sore 
throat, myalgia, diarrhoea, and severe 
pneumonia with tachypnoea (≥30 breaths 
per min), oxygen saturation ≤93% at rest, or 
PaO2/FiO2 ratio <300 mm Hg) with 
complication that can be associated with 
higher mortality rate including pneumonia, 
septic, and Acute Respiratory Distress 
Syndrome (ARDS).4-9 
Pathophysiology of COVID-19 
Pathophysiology of COVID-19 
related ARDS has similarities to other 
pneumonia. There is overproduction of 
early response proinflammatory cytokines 
including tumour necrosis factor (TNF), 
interleukin (IL)-6, and IL-1β that resulted in 
cytokine storm. Cytokine storm related to 
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the risk of vascular hyperpermeability, 
multiorgan failure, and eventually death.10 
Cytokine Storm Mechanism in COVID-
19 
 In-vitro cells study shown that at 
early stage of COVID-19 there is delayed 
release of cytokines and chemokines in 
respiratory epithelial cells, dendritic cells, 
and macrophages. Later, the cells secrete 
low levels of antiviral factors interferons 
(IFNs) and high levels of proinflammatory 
cytokines (IL-6, IL-1β, and tumour necrosis 
factor (TNF) and chemokines (C-C motif 
chemokine ligand (CCL)-2, CCL-3, and 
CCl-5). Coronavirus infected airway 
epithelial cells, THP-1 cells (monocyte 
cell), human peripheral blood monocyte-
derived macrophages, and dendritic cells 
that resulted in delayed but elevated levels 
of proinflammatory cytokines and 
chemokines.11-13 
 Patient with severe symptoms had 
significantly higher serum cytokines and 
chemokines levels than patient with mild to 
moderate symptom. This phenomenon are 
prompt by substantial number of 
neutrophils and monocytes in lung tissues 
and peripheral blood and lead to lung 
pathology.14,15  
 Patient with COVID-19 shown 
increasing levels cytokines as IL-1β, IFN-γ 
, IP-10, and monocyte chemoattractant 
protein 1 (MCP-1).4 This cytokines trigger 
the reaction of T-helper type 1 (TH1) 
cells.16 There is also increasing numbers of 
cytokines as IL-4 and IL-10 which inhibit 
the inflammatory response that secreted 
from TH2 cells. The serum levels of 
cytokines IL-2 and IL-6 in patient with 
COVID-19 influence the severity of the 
disease with higher levels mean more 
critically ill patients.7 Some study also 
shown elevated serum levels of granulocyte 
colony-stimulating factor, IP-10, MCP-1, 
macrophage inflammatory protein-1A, and 
TNF- α in patient with COVID-19 that 
treated in ICU compared to the one in 
general unit. The increasing cytokines are 
positively correlated with  disease severity.4 
More than 70% of COVID-19 
related pneumonia patients required 
mechanical ventilation and around 70% 
suffered ARDS.17 In patient with ARDS 
there are significantly increasing serum 
levels of cytokine that positively correlated 
with development and progression of the 
disease.18 Increasing cytokine that cause 
cytokine storm also play a role that 
determined multiple organs failure. 19 
 Several therapeutic approaches have 
been used to deal with cytokine storms in 
COVID-19 including IFN-λ, 
corticosteroids, Intravenous 
Immunoglobulin (IVIG), IL-1 antagonists, 
IL-6 antagonists, TNF blockers, IFN-αβ, 
chloroquine, and so on.13 
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Hyper-coagulation in COVID-19 
Infection triggers a responses that 
lead to coagulation. Coagulation itself 
limits the invasiveness of the pathogen.20 
Coagulation pathway leads to 
overproduction of proinflammatory 
cytokines. Thrombin promotes clot 
formation by activating platelets and 
converting fibrinogen to fibrin. Thrombin 
also stimulates inflammation through 
proteinase-activated receptors (PARs). 
Thrombin production is managed by 
negative feedback loops and anticoagulants 
such as antithrombin III, tissue factor 
pathway inhibitor, and the protein C 
system.21 These three anticoagulant 
mechanism impaired during the 
inflammation then imbalance of thrombin 
production and consumption occurs. 10  
The imbalance between 
procoagulant and anticoagulant induced the 
development of micro-thrombosis, 
disseminated intravascular coagulation 
(DIC), and multiorgan failure.22 In patient 
with COVID-19, coagulopathy defined as 
increasing prothrombin time (PT) > 3 
seconds, increasing activated partial 
thromboplastin time (aPTT) > 5 seconds, 
and increasing D-dimer  > 1.0 mcg/mL as 
main indicator.  Patient COVID-19 with 
severe pneumonia and associated with 
increasing mortality shown an elevated D-
dimer, increased PT, and elevation in IL-6. 
23  Increased IL-6 levels itself correlated 
with increased fibrinogen levels which 
increase fibrin and further clot promotion.24 
Anticoagulant in Patient with COVID-19 
 Anticoagulant such as heparin 
decrease the mortality rate. Patient COVID-
19 patient in Wuhan with Sepsis Induces 
Coagulopathy (SIC) score ≥ 4 or increased 
D-dimer more than 6 fold considered as 
more severe.22,25 Low molecular weight 
heparin (LMWH) therapy for at least 7 days 
show decrease mortality by 20% from 
52,4% to 32,8%.25 In New York, the 
anticoagulant therapy affect to the mortality 
of patient COVID-19 with 22.5% with 
median survival of 21 days compared with 
mortality rate of 22.8% with median 
survival of 14 days in patient without 
anticoagulant therapy.26 
 
Table 2. ISTH SIC scoring system10 
 




ARDS considered one of many 
complication of COVID-19 with highest 
mortality rate. This lung coagulopathy are 
established by localized tissue factor-
mediated thrombin generation and 
decreased bronchoalveolar plasminogen 
activator-mediated fibrinolysis.28,29 
Treatment using LMWH within 7 days 
onset of ARDS reduce the mortality up to 
35% % and the risk of 28 days mortality by 
around 37%.30 
 Treatment with systemic 
anticoagulant also shown significantly 
increased PT, aPTT, lactate dehydrogenase, 
ferritin, C reactive protein, and D-dimer 
compared to those who did not receive the 
treatment. The mortality of patient also 
associated with the duration of the 
anticoagulant treatment26. Low molecular 
heparin considered as a potential and 
effective anticoagulant in COVID-19 
patient with hyper-coagulation.  
 However, Heparin administration 
itself come with complication as bleeding 
events. Major bleeding define as 1) 
decreasing Haemoglobin (Hb) < 7 g/dL and 
required blood cell transfusion, 2) given 
minimal two units red blood cell transfusion 
within 2 days or 3) diagnose for internal 
bleeding including intracranial 
haemorrhage, hematemesis, melena, peptic 
ulcer with haemorrhage, colon, rectal, or 
anal haemorrhage, haematuria, ocular 
haemorrhage, and acute haemorrhagic 
gastritis. Among patient with anticoagulant 
therapy 3% individuals had bleeding event 
compared with 1,9% patient with bleeding 
event without anticoagulant therapy.26 
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